Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Neutrophil Extracellular Traps on Clinical Outcome after Subarachnoid Hemorrhage: A Translational Narrative Review.

Translational stroke research·2026
Same author

Democratizing Specialized Care in the Digital Age: Project ECHO as a Learning Environment for Continuing Professional Development.

Healthcare (Basel, Switzerland)·2026
Same author

Biomarkers of Cardioembolic Stroke in Thrombus Composition: Diagnostic Value of DNA and Fibrin Content.

European journal of neurology·2026
Same author

[Thromboinflammation in ischemic stroke: towards new therapeutic opportunities?]

Medecine sciences : M/S·2026
Same author

Sirtuin 1 is an endogenous NETosis inhibitor that becomes dysfunctional in diabetes.

Journal of leukocyte biology·2026
Same author

Loss of Fsr quorum sensing promotes biofilm formation and worsens outcomes in enterococcal infective endocarditis.

Nature communications·2026

Related Experiment Video

Updated: May 20, 2026

The Stroke Preclinical Assessment Network Multi-Laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo
06:38

The Stroke Preclinical Assessment Network Multi-Laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo

Published on: December 19, 2025

ADAMTS13 exerts a thrombolytic effect in microcirculation.

Marilena Crescente1, Grace M Thomas, Melanie Demers

  • 1Immune Disease Institute and Program in Cellular and Molecular Medicine, Children's Hospital Boston, Boston, MA 02115, USA.

Thrombosis and Haemostasis
|July 12, 2012
PubMed
Summary

Recombinant ADAMTS13 (a disintegrin-like and metalloprotease with thrombospondin type I repeats-13) effectively dissolves blood clots in vivo without causing bleeding. This finding suggests ADAMTS13 as a safer alternative to r-tPA for thrombolysis.

More Related Videos

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli
13:10

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli

Published on: September 25, 2016

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Related Experiment Videos

Last Updated: May 20, 2026

The Stroke Preclinical Assessment Network Multi-Laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo
06:38

The Stroke Preclinical Assessment Network Multi-Laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo

Published on: December 19, 2025

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli
13:10

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli

Published on: September 25, 2016

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Area of Science:

  • Biochemistry
  • Hematology
  • Vascular Biology

Background:

  • Recombinant tissue plasminogen activator (r-tPA) is a standard thrombolytic agent but carries risks of bleeding and variable efficacy.
  • ADAMTS13 (a disintegrin-like and metalloprotease with thrombospondin type I repeats-13) cleaves von Willebrand factor, down-regulating thrombus formation.

Purpose of the Study:

  • To investigate the in vivo thrombolytic efficacy and safety of recombinant ADAMTS13 (r-ADAMTS13) in a mouse model.
  • To compare the effects of r-ADAMTS13 with r-tPA and a vehicle control.

Main Methods:

  • Ferric chloride-induced thrombosis was created in mouse venules using intravital microscopy.
  • Recombinant ADAMTS13, r-tPA, or PBS (vehicle) with hirudin was applied to occluded vessels.
  • Thrombus dissolution, blood flow restoration, and bleeding incidence were evaluated.

Main Results:

  • r-ADAMTS13 significantly increased blood flow restoration compared to PBS (60% vs. 0% at 30 min, p<0.05).
  • Both r-tPA and r-ADAMTS13 reduced thrombus size, with no significant difference between them at 60 min.
  • Bleeding occurred in all r-tPA-treated mice, but was absent in r-ADAMTS13 and PBS groups.

Conclusions:

  • Recombinant ADAMTS13 demonstrates potent in vivo thrombolytic activity in venules.
  • Unlike r-tPA, r-ADAMTS13 achieves thrombolysis without associated hemorrhage.
  • ADAMTS13 presents a promising new therapeutic strategy for thrombolysis with an improved safety profile.